Integrating Every Facet of Insulin Delivery With Medtronic’s MiniMed Go

On January 12, 2026, the US Food and Drug Administration (FDA) announced its clearance of the Minimed Go, Medtronic’s new mobile application and multiple daily injection (MDI) system for the treatment of insulin-requiring type 1 diabetes and type 2 diabetes. The program coordinates between the InPen smart insulin pen with Abbott’s Instinct sensor and the MiniMed Go Smart MDI system, providing missed dose alerts, a dose calculator, guidance for missed or miscalculated doses, and easier provider collaboration through software reporting.1

Diabetes Dialogue hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, sat down to spotlight the device and its promising future in insulin delivery.

Check out the full episode on the MiniMed Go and other tech updates here.

The discussion frames MiniMed Go as a significant update to the existing InPen ecosystem, which Medtronic acquired several years ago. It emphasizes its potential to meaningfully improve care for people using multiple daily injections (MDI).

Isaacs and Bellini highlight that MiniMed Go introduces more advanced, intelligence-driven features compared with prior iterations. In contrast to retrospective reporting alone, the new app is intended to provide real-time, actionable guidance, such as identifying likely missed boluses or meals and prompting users with strategies to respond, including correction dosing. These features are designed to reduce common challenges in MDI therapy, such as insulin stacking or delayed treatment decisions, and to help improve overall time in range.

A central focus of the discussion is MiniMed Go’s integration with Medtronic’s new Instinct continuous glucose monitoring sensor, which is based on Libre 3 Plus technology and offers real-time glucose data with up to 15 days of wear. The panel contrasts this with prior InPen integrations, particularly with Dexcom, which involved a multi-hour data delay that limited usefulness for real-time decision-making. Real-time CGM integration is described as a major step forward, enabling users to quickly assess glucose trends, insulin-on-board, and dosing needs directly from their phones.

The hosts emphasize the importance of these advances for patients who prefer MDI over insulin pump or automated insulin delivery systems. While clinical guidelines encourage offering advanced insulin delivery technologies—especially for people with type 1 diabetes or insulin-deficient type 2 diabetes—many patients decline pumps due to lifestyle preferences, meal patterns, or treatment burden. MiniMed Go is positioned as a practical, lower-complexity option that still delivers meaningful clinical support for this population.

The conversation also situates MiniMed Go within the broader market landscape, noting that InPen is currently the only connected insulin pen available in the U.S., following the withdrawal or uncertainty surrounding other competitors. The panel expresses reassurance that Medtronic continues to invest in and support InPen, viewing this as critical for maintaining innovation and choice in MDI care. Isaacs and Bellini conclude with cautious optimism about future sensor integrations and a call for improved pharmacy-based access and reimbursement pathways to simplify prescribing and expand patient access to connected pen technology.

Editor’s Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.

References

1. Medtronic. Medtronic Diabetes announces FDA clearance for MiniMed Go Smart MDI system featuring Instinct sensor made by Abbott. January 12, 2026. Accessed January 21, 2026. https://news.medtronic.com/2026-01-12-Medtronic-Diabetes-announces-FDA-clearance-for-MiniMed-Go-TM-Smart-MDI-system-featuring-Instinct-sensor-made-by-Abbott